– ZANVASTRO ™ (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline – – TRYNGOLZA ® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a
Ionis reports third quarter 2026 financial results and highlights progress on key programs
calendar_today
November 9, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals